Cytosorbents Corporation (CTSO) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Cytosorbents Corporation (CTSO:NASDAQ), powered by AI.

Current Price
$0.40
P/E Ratio
-3.0
Market Cap
25M
Sector
Healthcare
What is the Cytosorbents Corporation stock price forecast?

Cytosorbents Corporation is currently trading at $0.40. View real-time AI analysis on Alpha Lenz.

What is Cytosorbents Corporation insider trading activity?

View the latest insider trading data for Cytosorbents Corporation on Alpha Lenz.

What is Cytosorbents Corporation's P/E ratio?

Cytosorbents Corporation's P/E ratio is -3.0.

Cytosorbents Corporation

NASDAQ · CTSO
$0.40+0.01(+3.04%)Pre-marketNASDAQ regular session 09:30–16:00 ET
Ask about Cytosorbents Corporation's future dividend policy...
Alpha Chat Insight

Cytosorbents Corporation trades at a P/E of -3.0 (undervalued) with modest ROE of -96.4%.

Ask for details

Company Overview

Cytosorbents Corporation is a biotechnology company that specializes in advanced blood purification technologies designed to treat life-threatening conditions in intensive care units and other hospital settings. The company's flagship product, CytoSorb, is a hemoadsorption cartridge that removes cytokines and other inflammatory mediators from blood. This device aims to help control excessive inflammation, which is a critical factor in numerous conditions such as sepsis, cardiac surgery, and trauma. Cytosorbents operates predominantly within the healthcare and medical technology sectors, with its technologies gaining attention for their potential impact on critical care and immunotherapy. Given its focus on innovative medical solutions, the company plays a pivotal role in advancing treatment protocols and improving patient outcomes. Headquartered in Princeton, New Jersey, Cytosorbents continues to expand its reach globally, participating in various clinical trials and partnerships to enhance the adoption and efficacy of its products in modern medical practice.

CEODr. Phillip P. Chan M.D., Ph.D.
SectorHealthcare
IndustryMedical Devices
Employees149

Company Statistics

FY 2025

Profile

$24.88MMarket Cap
$37.06MRevenue
0.00Shares Out
149Employees

Margins

71.48%Gross
-35.53%EBITDA
-38.42%Operating
-23.20%Pre-Tax
-22.12%Net

Valuation

-3.03P/E
4.21P/B
0.67EV/Sales
-3.63EV/EBITDA
-1.93P/FCF

Growth (CAGR)

8.08%Rev 3Yr
-1.24%Rev 5Yr
N/AOp Inc 3Yr
N/AOp Inc 5Yr
N/ANet Inc 3Yr
N/ANet Inc 5Yr

Returns

-17.91%ROA
-96.39%ROE
-13.08%ROIC

Financial Health

$6.25MCash & Cash Equivalents
$32.03MNet Debt
648.47%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Cytosorbents Corporation (ticker: CTSO) is a company listed on NASDAQ in the Healthcare sector (Medical Devices). It has approximately 149 employees. Market cap is $25M.

The current price is $0.4 with a P/E ratio of -3.03x and P/B of 4.21x.

ROE is -96.39% and operating margin is -38.42%. Annual revenue is $37M.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Cytosorbents Corporation (CTSO) Stock Forecast 2026 $0.40 — Price, Financials & Analyst Targets | Alpha Lenz